Clinical Trial: Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340216) titled 'Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis' on Dec. 19, 2025.

Brief Summary: This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Psoriasis

Intervention: DRUG: ARQ-154 Foam 0.3%

ARQ-154 Foam 0.3%

Recruitment Status: RECRUITING

Sponsor: Arcutis Biotherapeutics, Inc.

Disclaimer: Curated by HT Syndication....